ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Mustang Bio Announces First Subject Treated in CD20-targeted CAR T Cell Therapy MB-106 Trial
March 10, 2020Mustang Bio announced the first subject treated with the optimized MB-106 (CD20-targeted, autologous CAR T cell therapy) manufacturing process, developed in collaboration between Mustang and Fred Hutchinson Cancer Research Center ... -
Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein
May 09, 2019Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers ... -
Mustang Bio licenses gene therapy for bubble boy disease
August 16, 2018US-based biopharmaceutical firm Mustang Bio has entered an exclusive worldwide licence agreement with St. Jude Children’s Research Hospital for a new gene therapy to treat X-linked severe combined immunodeficiency (X-SCID or bubble boy disease).
Pharma Sources Insight January 2025
